For a 75-year-old bedridden woman with acute deep‑vein thrombosis, septic shock from a sacral pressure ulcer, acute kidney injury with metabolic acidosis, intubated for suspected pulmonary embolism, normal inferior vena cava size and dilated right ventricle, what are the risks and contraindications to systemic thrombolysis versus intravenous unfractionated heparin?

Intravenous unfractionated heparin is strongly recommended over systemic thrombolysis in this critically ill patient due to multiple absolute contraindications to thrombolytic therapy.

This 75-year-old bedridden woman with suspected PE and RV dilation presents with multiple absolute contraindications to systemic thrombolysis that make it an unacceptably dangerous option despite the presence of RV dysfunction.

Critical Contraindications to Thrombolysis

Active bleeding risk from sacral pressure ulcer: The infected sacral sore in the setting of septic shock represents an active bleeding source with impaired wound healing. Systemic thrombolysis would carry an extremely high risk of uncontrolled hemorrhage from this site 1.

Septic shock and coagulopathy: Sepsis-induced coagulopathy is common in septic shock and significantly amplifies bleeding risk. The Surviving Sepsis Campaign guidelines emphasize that patients with severe coagulopathy or active bleeding should not receive pharmacologic anticoagulation prophylaxis, let alone full-dose thrombolysis 2.

Metabolic acidosis and acute kidney injury: The metabolic acidosis suggests severe tissue hypoperfusion and multiorgan dysfunction. AKI complicates anticoagulation monitoring and drug clearance. While the 2017 Surviving Sepsis guidelines suggest against bicarbonate therapy for pH ≥7.15, severe acidosis below this threshold indicates profound hemodynamic instability that would make thrombolysis extremely hazardous 2.

Age and frailty: At 75 years old and bedridden, this patient has significantly increased bleeding risk. Studies consistently show higher bleeding rates in elderly patients, particularly women over 60 1.

Recommended Management Strategy

Immediate anticoagulation with IV unfractionated heparin is the appropriate choice 3:

• Weight-based dosing: 80 IU/kg bolus followed by 18 IU/kg/hour infusion 4, 5, 1
• APTT monitoring: Target APTT ratio 1.5-2.5 (45-75 seconds), checked 4-6 hours after bolus and after any dose adjustment 4
• Advantages in this patient: UFH has a short half-life (allowing rapid reversal if bleeding occurs), can be monitored closely in the ICU setting, and is preferred in hemodynamically unstable patients and those with severe renal impairment 5

Why not LMWH? Although generally preferred over UFH for VTE treatment 5, LMWH is contraindicated when creatinine clearance <30 mL/min due to accumulation risk 5. This patient's AKI makes UFH the safer choice as it doesn't rely on renal clearance and can be rapidly reversed.

Risk Stratification Context

Despite the dilated RV suggesting intermediate-high or high-risk PE, the 2019 ESC guidelines explicitly state that routine systemic thrombolysis is not recommended in intermediate-risk PE 3. Thrombolysis is reserved for:

• High-risk PE with hemodynamic instability (hypotension/shock) as first-line therapy
• Rescue therapy if hemodynamic deterioration occurs despite anticoagulation 3

Normal IVC size argues against massive PE with severe RV afterload, as massive PE typically shows IVC dilation from RV failure and elevated central venous pressure.

Management Algorithm

1. Initiate IV UFH immediately without waiting for confirmatory imaging if PE is strongly suspected 3
2. Address septic shock aggressively: Source control of sacral ulcer, broad-spectrum antibiotics, vasopressor support
3. Correct coagulopathy: Monitor platelet count every 2-3 days (days 4-14) for heparin-induced thrombocytopenia 5, 1
4. Monitor for bleeding: Daily hemoglobin, unexplained hypotension, or hematocrit drops mandate immediate evaluation 1
5. Reserve thrombolysis only if: Patient develops refractory hemodynamic collapse despite maximal support—then consider catheter-directed therapy over systemic thrombolysis to minimize bleeding risk 3

Critical Pitfalls to Avoid

• Do not give systemic thrombolysis in the presence of active bleeding sources, severe sepsis with coagulopathy, or recent surgery/trauma 1
• Do not use LMWH with severe AKI (CrCl <30 mL/min) 5
• Do not delay anticoagulation while awaiting definitive imaging if clinical suspicion is high 3
• Do not overlook HIT: Monitor platelets closely as UFH carries up to 5% HIT risk in high-risk populations 5

The presence of septic shock, active bleeding risk, severe AKI, and advanced age create an overwhelming contraindication profile that makes anticoagulation with UFH the only rational choice, with thrombolysis reserved solely as a last-resort rescue therapy if the patient deteriorates to frank cardiovascular collapse despite maximal medical support.